Business
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PONTE VEDRA, Fla., August 11, 2025--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2289,"height":530,"url":"https://media.zenfs.com/en/business-wire.com/a19da8f4c109fad0cde2bb0ff57519a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OLVS0jm5Re7nOgk_cc9uvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a19da8f4c109fad0cde2bb0ff57519a6","width":960,"height":222},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/3syCvyU09YomWeQnWosaiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a19da8f4c109fad0cde2bb0ff57519a6","width":1200,"height":278}},"lazy":false},{"type":"text","content":"Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"Tecarfarin can potentially address critical treatment gaps in patients with ESKD","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"Pivotal step forward in pursuit of ESKD + Atrial Fibrillation (AFib) registration trial","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"PONTE VEDRA, Fla., August 11, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing transformative therapeutics that specifically address limitations of current anticoagulation therapy, today reported its financial results for the second quarter ended June 30, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin.","length":430,"tagName":"p"},{"type":"text","content":""We continue to advance our goal of developing transformative therapeutics to address the gaps in current anticoagulation therapy for patients with complex needs," said Quang X. Pham, Chairman & CEO. "This commitment is reflected in our strategic plan to initiate a clinical trial for tecarfarin in end-stage kidney disease (ESKD) for patients transitioning to dialysis. There is a critical need for safe, effective anticoagulants for use in ESKD patients, and tecarfarin’s orphan drug and fast-track designations in ESKD patients with atrial fibrillation (AFib) underscore this need. We are very excited to advance thi...